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Figure 2. Overall survival (OS)
Figure 3. OS by disease status at transplantation
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were myeloablative in 20 patients and reduced-intensity in
9. Twenty-seven patients achieved neutrophil engraftment
at a median day of 19 (range, 10-34). The cumulative inci-
dence of neutrophil engraftment was 93.1% at day 42 (pa-
tients engrafted, n¼27; dead before day 19, n¼2). At 3 years,
the cumulative incidence of relapse and non-relapse mor-
tality was 32.3% and 14.0%, respectively. In 15 patients who
did not achieve CP before transplantation, 11 patients (73.3%)
achieved CR after transplantation. With a median follow-up
of survivors of 1144 days (range, 127-3705), overall survival
(OS) and event free survival (EFS) at 3 years was 63.2% and
56.3%, respectively. In univariate analysis, the variables that
inﬂuenced on OS were disease status at transplantation (CP
vs. AP/BC, 85% vs. 42%, p¼0.012), karyotype (sole Ph-chro-
mosome vs. additional cytogenetic abnormalities, 90% vs.
47.5%, p¼0.042) and conditioning regimen (MAC vs. RIC,
72.7% vs. 41.7%, p¼0.039). In multivariate analysis, the onlyvariable that inﬂuenced on OS was disease status at trans-
plantation (p¼0.015).
Conclusion: We concluded that allogeneic hematopoietic
cell transplantation from any cell sources could become a
promising option for the patients with CML in advanced
stage, especially if they achieved CP before transplantation.430
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Background: Matching for HLA-DPB1 lowers relapse risk in
allogeneic hematopoietic stem cell transplantation (ASCT),
but this locus is not in linkage disequilibrium with the
remainder of the HLA genes, makingmatchingmore difﬁcult.
Recent studies have suggested that after classifying HLA-
DPB1 mismatches based on T-cell epitope group, avoiding
non-permissive mismatches leads to improved survival. We
tested this hypothesis in our patient population.
Methods: We conducted a retrospective analysis of 78 pa-
tients who underwent ASCT at the Mayo Clinic 1/1/2008 -
12/21/2010. Patients with unrelated volunteer donors were
matched for HLA-A, B, C, DRB1 and DQB1 loci (10/10) at the
allele level without consideration of the HLA-DPB1 locus.
Patient and donor HLA-DPB1 genotyping was performed by
reverse SSO typing and the ImMunoGeneTics/HLA (IMGT/
HLA) T-cell epitope matching algorithm was used to deter-
mine mismatch status as permissive or non-permissive.
Results: Of 78 donor recipient pairs, therewere 13HLA-DPB1
matches, 42 permissive mismatches, and 23 non-permissive
mismatches (10 in the graft-vs-host [GvH] direction,13 in the
host-vs-graft [HvG] direction). In a univariate analysis, when
matches and permissive mismatches were combined into a
group and compared to non-permissive mismatch, therewas
no signiﬁcant difference in overall survival (p¼0.31), relapse
(p¼0.79), or neutrophil or platelet engraftment (p¼0.23 and
p¼0.99, respectively). No signiﬁcant difference was observed
in acute graft-vs-host disease (aGVHD; p¼0.25) or grade II-IV
aGVHD (p¼0.62) among the matched, permissive mis-
matched, and non-permissive mismatched groups. The
permissivemismatched group showed an increase in chronic
GVHD (cGVHD) over the matched and the non-permissive
mismatched groups that neared signiﬁcance (p¼0.052).
In univariate analyses, for non-permissive mismatches,
the GvH mismatch direction trended toward reduced sur-
vival (p¼0.26), increased relapse (p¼0.13), increased aGVHD
(p¼0.064), and increased cGVHD (p¼0.22).
Conclusions: We did not identify any signiﬁcant differ-
ences in survival, relapse, engraftment, or acute or chronic
GVHD among the patients with HLA-DPB1 donor matches,
permissive mismatches, and non-permissive mismatches,
although our study was limited by small sample size.
Further work from large databases is necessary to fully
understand the impact on clinical outcomes of HLA-DPB1
mismatches.
